Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.51 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TERT | O14746 | 2/20 | 0.47 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2326201 | 0.83 | LTA4H (0.64) | HRH3SIGMAR1DRD2SLC6A4SLC6A3 | |
| SCHEMBL5437780 | 0.81 | SLC6A3 (0.67) | HRH3SIGMAR1DRD2SLC6A4SLC6A3 | |
| SCHEMBL18917604 | 0.77 | LTA4H (0.75) | HRH3SIGMAR1DRD2SLC6A4SLC6A3 | |
| SCHEMBL4090273 | 0.76 | ATM (0.68) | HRH3SLC6A4ATML3MBTL1 | |
| SCHEMBL18917601 | 0.74 | SLC6A3 (0.77) | HRH3SIGMAR1DRD2SLC6A4SLC6A3 | |
| SCHEMBL15351939 | 0.73 | CYP2A6 (0.43) | SIGMAR1SLC6A3L3MBTL1 | |
| SCHEMBL15352151 | 0.73 | CYP2A6 (0.43) | SIGMAR1L3MBTL1 | |
| SCHEMBL5855257 | 0.73 | CYP2A6 (0.43) | SIGMAR1LTA4HL3MBTL1 | |
| SCHEMBL8780108 | 0.73 | ATM (0.59) | HRH3SLC6A4LTA4HATML3MBTL1 | |
| SCHEMBL2452213 | 0.73 | HRH3 (0.70) | HRH3SIGMAR1SLC6A4SLC6A3HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7145005-B2 | 2-(6-{2-[(2R)-2-Methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation | ABBOTT LABORATORIES (US) | 2006-12-05 | — | — | US | claimed |
| US-20050256127-A1 | 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation | ABBVIE INC. | 2005-11-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256127-A1 | 2-(6-{2-[(2R)-2-methyl-1-pyrrolidin-1-yl]-ethyl}-2-naphthalen-2-yl)-2H-pyridazin-3-one salts and their preparation | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYP2J2, NUP188 | HRH3 3738/4885SIGMAR1 3180/4885DRD2 1946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.